CPD: Side-by-side comparison of old vs new systems

Dr Charlotte Hespe

writer

Dr Charlotte Hespe

MBBS (Hons), DCH (Lon), FRACGP, FAICD, GCUT (UNDA), Head, General Practice and Primary Care Research, School of Medicine, Sydney, The University of Notre Dame Australia

Claim CPD for this activity

Educational Activities (EA)

0 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0 minutes

These are activities that require reflection on feedback about your work.

MO
0 minutes

These are activities that use your work data to ensure quality results.

Dr Charlotte Hespe

 
How is the new CPD system different?

In Part 1 and Part 2 of my series on CPD changes, we had a good look at what are the CPD program is looking like for next year.

But what really are the differences between what I do now and what will happen from 2023?

Here’s a side-by-side comparison:

There is no time allocated against completion of a PDP plan but the RACGP myCPD will automatically allocate five hours to everyone who uses the program to prepare their plan. It is NOT expected that a PDP will take five hours to complete. This time is being allocated in the expectation that five hours might be spent thinking, planning and reviewing for your CPD over the entirety of the year.

Each year, AHPRA will require every CPD home to audit 5% of the enrolled medical practitioners’ CPD diaries and PDPs. The CPD Homes will themselves be subjected to an audit by AHPRA to check that they are doing what they have been accredited to do!

As I write this article, I have not yet seen any details about the organisations who have put in Expressions of Interest to become CPD Homes. 31 August was the closing date for all EOIs to be submitted.

As more information emerges, we will update you about any breaking news!

I hope that after reading all three of the CPD articles you feel less confused about what will happen next year – and more confident that your specialist college will be able to assist you in navigating all of the changes both easily and without any complications!

Dr Charlotte Hespe is a GP based in Sydney and the Head of General Practice and Primary Care Research at the School of Medicine at The University of Notre Dame Australia.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rod Baber

Prof Rod Baber

Menopause and MHT: Maximising Benefits & Minimising Risks

Dr Fiona Chan

Dr Fiona Chan

Multiple Sclerosis vs Antibody Disease – What GPs Need to Know

Prof Andrew Sindone & Dr Ted Wu

Prof Andrew Sindone & Dr Ted Wu

Using SGLT2 to Reduce Cardiovascular Death in T2D – Important Updates for GPs

Dr Shannon Thomas

Dr Shannon Thomas

Peripheral Arterial Disease

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Dr Charlotte Hespe

writer

Dr Charlotte Hespe

MBBS (Hons), DCH (Lon), FRACGP, FAICD, GCUT (UNDA), Head, General Practice and Primary Care Research, School of Medicine, Sydney, The University of Notre Dame Australia

Test your knowledge

Recent articles

Latest GP poll

Has a clinic you work at ever received an unfair negative online review?

Yes

0%

No

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease